In High-Stakes Chip Deal, China Has Regulatory Leverage
A strategic struggle over tech supremacy frames Nvidia's pending acquisition of Mellanox.
The deal requires the approval of the Chinese regulator, the State Administration for Market Regulation. Credit: Martijn Boer, Flickr
While the Covid-19 pandemic rages, China and the United States continue to spar warily over national security, technology and deal-making. In this fight, the canary in the coal mine is Nvidia’s pending $6.9 billion acquisition of Mellanox.
Nvidia, a U.S. company, agreed to acquire Mellanox, an Israeli company with U.S. operations, 13 months ago. Both are in the semiconductor industry, making high-end chips to power supercomputers and much of the cryptocurrency industry. For Nvidia, f
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
